Startup For 10: Neuronostics

For today’s Startup for 10, we’re delighted to feature the fantastic team from Neuronostics, the neurology-focused healthtech tackling the “epilepsy diagnostic lottery” with their groundbreaking BioEP technology.

Fresh from winning Healthtech Business of the Year and the People’s Choice Award at this year’s SPARKies, Founder John Terry and Partnerships Development Officer Becca Hogg tell us more about their mission and the impact of their work.

1.) In your own words – what do you do?

We are ending epilepsy’s diagnostic lottery. Right now, people can wait months or years for answers while EEGs come back inconclusive over 70% of the time. That’s broken.

BioEP changes the game. It’s the world’s first digital biomarker of epilepsy, that analyses as little as 20 seconds of routine EEG data to reveal seizure risk that human eyes miss. We give clinicians an extra layer of insight when everything appears “normal”, turning uncertainty into clarity.

Our team of mathematicians, software engineers and clinical experts share one mission: getting people the answers they deserve, faster.

2) What’s the most exciting thing about what you’re doing?

Watching BioEP transform real clinical decisions. Our PRISTINE study showed clinicians changed their seizure risk assessment in over 40% of cases after seeing BioEP results. This isn’t just statistical significance, it’s proof that BioEP transforms clinical practice when standard EEGs appear normal.

We are also scaling fast. We secured £600K from the NHS to develop BioEP suitable for children, we have got prognostic tools in development, and our partnership with Stratus, the US’s largest EEG provider, opens doors to millions of patients globally. Plus, we’ve just gained regulatory approval in the UAE, whilst working towards our FDA submission.

3) What are you most proud of so far?

Turning academic research into a regulated medical device delivering real-world impact is no small feat in MedTech. Receiving external validation of our approach makes us especially proud. In the past month alone our co-founder, Professor John Terry, was elected to the Academy of Medical Sciences: recognition of the rigorous science underpinning everything we do. Whilst receiving the People’s Choice Award at the Sparkies shows that our mission is resonating widely within the Tech community.

4) What have you found most difficult about being a startup?

Healthcare’s deliberate pace. You have got to prove safety, earn trust and meet every regulatory standard whilst trying to drive meaningful change. That’s the right approach, but it can test your patience as well as your investors’ patience!

Translation can be tough too, turning complex neuroscience into something that resonates with busy clinicians and anxious families. We have learned to tell our story clearly without over-promising.

5) What would you do differently if you started now?

Trust our own instincts more. When we first started we felt we didn’t understand the commercial landscape or how to navigate it. We weren’t well networked and finding impartial advice was tricky. Remember when you start a company, you know the space better than anyone else. At the same time there’s lots of things you won’t know. Knowing when you need advice and who you can trust is key. This is why organisations like TechSpark are powerful. They enable you to network with others facing the same challenges you are.

6) Where do you think you’ll be in 12 months?

Embedded across more NHS Trusts and expanding internationally. Building on our new partnership with Stratus we hope to make strides in the UAE, whilst ensuring our FDA approval is submitted.

Product-wise, we’ll be looking to launch our childhood epilepsy tool and developing prognostic capabilities. Ultimately, BioEP won’t just diagnose epilepsy, it will predict treatment responses and track patient progress. 

7) What excites you most about the future of medtech?

The shift from reactive, hospital-based care, to proactive and community-based. With point of care EEG systems developing rapidly, there’s huge potential for tools like BioEP to be able to provide people who have had a seizure with the answers they deserve sooner and from the comfort of their home.

8) What tools/people/services/organisations from the cluster have helped you most?

The University of Exeter first launched our translation from research to impact. SETsquared and Creative Destruction Lab helped accelerate our journey. Networking events from TechSpark, Tech South West, VWV and many others have all helped us to build relationships and trust.

The most important organisations are of course the NHS Trusts, whose patients and clinicians have been willing to trial BioEP and share meaningful feedback.

9) What’s the best thing about the Bristol & Bath tech cluster?

Pure collaboration. We spun out of Exeter but chose to locate in Bristol, thanks to its unique blend of tech innovation, world-class research and healthcare expertise.

We are positioned at the heart of a thriving ecosystem. Whether partnering with NHS Trusts, tapping into academic networks, or learning from other mission-driven start-ups, there’s genuine momentum here.

Organisations like TechSPARK and SETsquared create spaces where innovation isn’t just nurtured, it’s challenged in exactly the right way. It’s about building technology that works in the real world, and this ecosystem gets that completely.

10) Where can we find out more about you?

Visit www.neuronostics.com or find us on LinkedIn (https://www.linkedin.com/company/neuronostics/) where we share updates on new pilots, partnerships and publications.

If you’re a clinician, investor or someone affected by epilepsy who wants to chat, our inbox is always open.